MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
ELVN — Enliven Therapeutics, Inc. Common Stock
NasdaqEnliven Therapeutics, Inc. Common Stock
$46.97
+0.76(+1.64%)
- O
- 47.38
- H
- 47.43
- L
- 45.92
- V
- 1.12M
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About ELVN
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateFeb 24, 2023
Employees67
Stock ExchangeNasdaq
Ticker SymbolELVN
Key Financial Statistics
| Market Cap | $3.44B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $14.79 - $62.32 |
| 52-Week Avg Volume | 1.11M |
| VWAP | $46.83 |
| Transactions | 12,586 |
| Total Recorded Bars | 1,648 days |